CBD and CBG May Be the First Drug for Fatty Liver Disease

Fatty liver disease has no approved drug treatment. Not one. Despite affecting roughly one in three adults worldwide and standing as the leading cause of chronic liver disease in developed nations, the pharmaceutical pipeline has produced nothing that clinicians can prescribe specifically for the condition. That may be about to change, and the answer is coming from an unlikely corner of pharmacology.

A study published in March 2026 in the British Journal of Pharmacology has demonstrated that two non-intoxicating cannabinoids — cannabidiol (CBD) and cannabigerol (CBG) — can significantly reduce liver fat accumulation and restore metabolic balance in preclinical models of metabolic dysfunction-associated steatotic liver disease (MASLD), the condition formerly known as non-alcoholic fatty liver disease (NAFLD).

The findings are not incremental. They represent a mechanistic breakthrough that reframes how cannabinoids interact with cellular energy metabolism — and they arrive at a moment when the medical community is desperate for solutions.

The Scale of the Problem

MASLD is a quiet epidemic. An estimated 30% of the global adult population has some degree of fatty liver disease, a number that has climbed steadily alongside obesity, type 2 diabetes, and metabolic syndrome. In the United States alone, prevalence exceeds 100 million people. The condition progresses silently through stages: simple steatosis (fat accumulation), steatohepatitis (inflammation), fibrosis, and eventually cirrhosis or hepatocellular carcinoma.

The clinical challenge is straightforward but brutal. Weight loss of 7-10% of body weight can reverse early-stage MASLD, but fewer than 10% of patients achieve and sustain that target. Bariatric surgery works but carries its own risks and is not scalable to a population-level problem. Resmetirom (Rezdiffra), approved by the FDA in March 2024 for MASH with moderate fibrosis, was the first drug to target the condition directly, but it addresses a narrow slice of the patient population and requires liver biopsy for diagnosis. The vast majority of MASLD patients — those in early-to-moderate stages — have nothing.

This is the gap that CBD and CBG appear positioned to fill.

What the Study Found

The research team used a well-established high-fat diet model to induce MASLD and then administered CBD, CBG, or a combination of both over a treatment period of several weeks. The results were striking across multiple endpoints.

Animals receiving CBD showed a 28% reduction in hepatic triglyceride accumulation compared to untreated controls. CBG performed even better, achieving a 34% reduction. The combination of both cannabinoids produced a 41% reduction — suggesting additive or mildly synergistic effects — consistent with the entourage effect — rather than redundant mechanisms.

But fat reduction was only part of the story. Treated groups showed significant improvements in insulin sensitivity, with fasting glucose levels dropping toward normal ranges. Liver enzyme markers — ALT and AST, the standard clinical indicators of hepatocyte damage — declined substantially, indicating reduced cellular injury. Inflammatory cytokine profiles shifted away from the pro-inflammatory state characteristic of disease progression.

Perhaps most importantly, histological examination revealed reduced fibrotic markers in treated animals, suggesting that CBD and CBG may not only prevent fat accumulation but actively slow the progression from simple steatosis toward the more dangerous inflammatory and fibrotic stages.

The Phosphocreatine Buffering Mechanism

The most scientifically significant aspect of this research is not that cannabinoids reduced liver fat — prior studies had hinted at this possibility — but how they did it.

The research team identified a previously uncharacterized mechanism: CBD and CBG enhance phosphocreatine buffering in hepatocytes. Phosphocreatine is a high-energy phosphate compound that serves as a rapid ATP regeneration system. In healthy cells, the creatine kinase shuttle moves high-energy phosphate groups between mitochondria (where ATP is produced) and the cytoplasm (where ATP is consumed). This system acts as an energy buffer, smoothing out the peaks and valleys of cellular energy demand.

In MASLD, this buffering system becomes impaired. Mitochondrial dysfunction — a hallmark of fatty liver disease — disrupts the creatine kinase shuttle, creating energy bottlenecks that force hepatocytes to rely increasingly on lipogenesis (fat synthesis) as an alternative energy storage mechanism. The liver, in effect, starts hoarding fat because its normal energy relay system is broken.

CBD and CBG appear to restore this relay. By upregulating creatine kinase expression and improving mitochondrial membrane potential, these cannabinoids re-establish efficient phosphocreatine cycling. The cell regains its ability to manage energy flow without resorting to excessive fat storage. It is an elegant mechanism — rather than blocking fat synthesis directly (the approach most pharmaceutical candidates have taken), cannabinoids fix the upstream energy management problem that drives fat accumulation in the first place.

Explore the study data in our Liver Health Research Tracker below.

This mechanistic distinction matters enormously for clinical translation. Drugs that directly inhibit lipogenesis often produce compensatory metabolic effects — the body finds other ways to store energy, or the sudden mobilization of hepatic fat creates downstream problems. By targeting the energy buffering system, CBD and CBG work with the cell’s natural metabolism rather than against it.

Context: Prior Cannabinoid Liver Research

This study does not exist in a vacuum. The endocannabinoid system has been implicated in liver metabolism for over a decade. CB1 receptors, which are activated by THC, are known to promote hepatic lipogenesis — a finding that initially raised concerns about cannabis and liver health. However, CB1 antagonists (most notably rimonabant) failed in clinical trials due to psychiatric side effects, including depression and suicidality.

CBD and CBG operate through different pathways entirely. CBD is a negative allosteric modulator of CB1 and has complex interactions with serotonin receptors, TRPV1 channels, and PPARs — the last of which is directly relevant to lipid metabolism. CBG, the precursor molecule from which other cannabinoids are synthesized in the plant, has its own distinct receptor profile and has shown anti-inflammatory properties in gastrointestinal models.

Previous smaller studies had shown CBD could reduce hepatic steatosis in isolated cell cultures and in short-duration animal models, but the phosphocreatine mechanism had not been identified. A 2022 study in Frontiers in Pharmacology demonstrated CBD’s ability to modulate lipid metabolism gene expression in hepatocytes, but the energetic mechanism linking mitochondrial function to fat accumulation was missing. The current study fills that gap with a coherent mechanistic narrative.

CBG has received less attention in liver research, making its strong performance in this study particularly notable. As one of several minor cannabinoids now drawing serious research interest, CBG is typically present in low concentrations in mature cannabis plants (most is converted to THC or CBD during growth), CBG has been historically understudied. Recent advances in CBG-dominant cultivar breeding and biosynthetic production have made research-grade CBG more accessible, enabling studies like this one.

The Road to Clinical Application

Preclinical results, however compelling, are not treatments. The gap between a well-designed animal study and an FDA-approved drug is measured in years, hundreds of millions of dollars, and a gauntlet of regulatory requirements that most candidates do not survive.

For CBD and CBG to become MASLD treatments, several steps must occur.

Phase I clinical trials would establish safety profiles and dosing ranges in healthy volunteers and early-stage MASLD patients. CBD has a significant advantage here: it already has FDA approval as Epidiolex for seizure disorders, meaning extensive human safety data exists. CBG lacks this regulatory history and would require more foundational safety work.

Phase II trials would test efficacy in defined patient populations. The choice of endpoints will be critical. The FDA has traditionally required liver biopsy to demonstrate histological improvement in MASH trials, but non-invasive biomarkers (MRI-PDFF for fat quantification, FibroScan for fibrosis staging) are gaining regulatory acceptance. If the FDA permits non-invasive endpoints, trial costs and patient recruitment barriers drop dramatically.

Phase III trials would need to demonstrate statistically significant improvement over standard of care (currently lifestyle modification alone) in large, diverse patient populations. Given the high placebo response rates in MASLD trials and the slow progression of the disease, these studies typically require 12-18 months of treatment and thousands of participants.

Formulation and delivery present additional challenges. The doses used in the preclinical study will need to be translated to human-equivalent doses, and the poor oral bioavailability of both CBD and CBG (typically 6-19% for CBD) may necessitate novel formulation approaches such as lipid-based nanoparticle delivery systems or pro-drug strategies.

One possible accelerated pathway: a pharmaceutical company could pursue a 505(b)(2) application for CBD, leveraging existing Epidiolex safety data while presenting new efficacy evidence for MASLD. This would not be a supplement or wellness product — it would be a prescription pharmaceutical with a specific disease indication. For CBG, the pathway would likely require a full New Drug Application (NDA) given the lack of prior approval.

What This Means for Patients

For the estimated 100 million Americans with some degree of fatty liver disease, this research offers something that has been in short supply: a plausible mechanism for a pharmacological intervention that addresses root causes rather than symptoms.

This is not a reason to self-medicate with CBD or CBG supplements. Over-the-counter cannabinoid products are unregulated, inconsistently dosed, and have not been tested for hepatic efficacy at any dose. They also carry potential drug interactions with common medications that patients should discuss with their physicians. Some CBD products have actually been associated with liver enzyme elevations at high doses — a finding that underscores the importance of precise dosing and pharmaceutical-grade formulation.

What this research does is validate a direction. The phosphocreatine buffering mechanism gives drug developers a clear target and cannabinoid pharmacology a clear rationale. If clinical trials confirm what preclinical data suggests, CBD and CBG could become the first approved treatments for a disease that affects a third of the adult world.

The liver disease community has been waiting a long time for this. The wait is not over, but for the first time, there is a scientifically rigorous reason to believe it will end.